Terms: = Thyroid cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
4 results:
1. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
2. Novel TMEM173 Mutation and the Role of Disease Modifying Alleles.
Keskitalo S; Haapaniemi E; Einarsdottir E; Rajamäki K; Heikkilä H; Ilander M; Pöyhönen M; Morgunova E; Hokynar K; Lagström S; Kivirikko S; Mustjoki S; Eklund K; Saarela J; Kere J; Seppänen MRJ; Ranki A; Hannula-Jouppi K; Varjosalo M
Front Immunol; 2019; 10():2770. PubMed ID: 31866997
[TBL] [Abstract] [Full Text] [Related]
3. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells.
Lim ST; Jeon YW; Gwak H; Kim SY; Suh YJ
Mol Med Rep; 2018 Apr; 17(4):5581-5588. PubMed ID: 29436642
[TBL] [Abstract] [Full Text] [Related]
4. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
Couto JP; Almeida A; Daly L; Sobrinho-Simões M; Bromberg JF; Soares P
PLoS One; 2012; 7(10):e46869. PubMed ID: 23056499
[TBL] [Abstract] [Full Text] [Related]
